Biocodex unifies pharmacy sales in France with Veeva CRM |

Biocodex unifies pharmacy sales in France with Veeva CRM |

Newly merged pharmaceutical sales teams adopt a single digital platform for more effective management of pharmacy orders

Barcelona, ​​Spain, May 10, 2022 / PRNewswire / – Veeva Systems (NYSE: VEEV) today announced that Biocodex, a family-owned multinational pharmaceutical company, has adopted Veeva CRM to drive more efficient pharmacy sales in France. Following its recent acquisition of Laboratories IPRAD, Biocodex is leveraging Veeva CRM’s pharmacy order management and store control capabilities to effectively orchestrate and align complex sales processes from order acquisition to delivery.

“As we shift more than half of our business to over-the-counter products and move to an increasingly pharmacy-oriented network, we need flexibility in our sales channels. Veeva CRM helps us to quickly bring in new representatives so they can conduct business engagements. great impact with various pharmacies and wholesalers, “said Emilie Perthuiset, general manager of France to the Biocode. “Our field teams can now improve product visibility as they quickly negotiate orders with accurate pricing and discounts determined in-store.”

In less than six months, Biocodex consolidated hundreds of disparate contracts and began coordinating interactions with several new stakeholders on Veeva CRM. With an advanced pharmacy order management and store control solution, the French pharmaceutical company is automating administrative tasks for its representatives so they can leverage their efforts where it matters most, accelerating order processing in so that the products arrive faster on the shelf.

“Merging the product portfolios of Biocodex and IPRAD into a single solution will allow reps to save time negotiating a single order, so they can focus on inventory controls and product training,” he said. Rohan Poole, senior director of commercial strategy at Veeva. “This can help strengthen relationships between pharmacies and representatives and improve the customer experience, both of which are crucial as Biocodex expands pharmacy sales. France. “

Using Veeva CRM, Biocodex representatives get useful information throughout the sales process, including better visibility into order history, invoice status, past trades and current market prices. As part of Veeva CRM, Veeva CRM Approved Email will help their field teams stay compliant while sending order confirmations and educational product information.

Additional information

For more information on Veeva CRM, visit:

Connect with Veeva on LinkedIn:

Follow @veeva_eu on Twitter:

About Biocode

Biocodex is a family-owned pharmaceutical company that has grown from a French microbiota pioneer in the 1950s to an international pharmaceutical player by diversifying its products and expanding its geographic footprint. Biocodex offers healthcare solutions to patients in more than 120 countries through its long-term operations or partnerships. Learn more about Biocodex at

Information on Veeva systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves over 1,000 customers, from the world’s largest pharmaceutical companies to emerging biotechnology. As a utility company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries in which it operates. For more information, visit

Veeva Forward-Looking Statements

This release contains forward-looking statements regarding Veeva products and services and the anticipated results or benefits of using our products and services, including some of our new solutions and applications that are still in development or not generally available. These statements are based on our current expectations. Actual results, availability and any future events relating to these products and services may differ materially from those anticipated or provided in this release and we are under no obligation to update such statements. There are a number of risks that can adversely impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the term ended January 31, 2022which you can find here (a summary of the risks that may impact our business can be found on pages 13 and 14) and in our subsequent SEC filings, which you can access at

Logo –


Leave a Comment

Your email address will not be published.